

# **ON**Concept®


A STRATEGIC COLLABORATION IN THE FIELD OF ONCOLOGY







www.onconceptpharma.com



## **ON**Concept®

## A strategic collaboration in the field of oncology

Three independent and certified European pharmaceutical companies - Bluepharma, Welding and Helm - united to form a leading partnership for complex, differentiated and high potency products.







## **Know-how, track-record** and expertise

Combining their strengths, the **ONConcept®** alliance is providing:

- Large basket of oncology products and other products.
- Integrated solutions and services covering the full value chain.
- EU-based development and manufacturing site.
- Sound in-house scientific, regulatory and commercial expertise.
- International networks and global experience.
- Flexible adaptation to product- and customer-specific needs.







## ONConcept® Product Basket

| INN                    | Reference Product   | Strength                      | Dosage<br>Form | Indication  |
|------------------------|---------------------|-------------------------------|----------------|---|
| Abiraterone<br>Acetate | Zytiga®             | 250mg, 500mg                  | Tablets        | Prostate Cancer   |
| Cabozantinib           | Cabometyx®          | 20mg, 40mg, 60mg              | Tablets        | Renal Cell and Hepatocellular Carcinomas,<br>Differentiated Thyroid Cancer  |
| Eltrombopag            | Revolade®/Promacta® | 12.5mg, 25mg, 50mg, 75mg      | Tablets        | Thrombocytopenia, Severe Aplastic Anemia  |
| Enzalutamide           | Xtandi <sup>®</sup> | 40mg, 80mg, 120mg, 160mg      | Tablets        | Prostate Cancer   |
| Fingolimod             | Gilenya®            | 0.25mg, 0.5mg                 | Capsules       | Multiple Sclerosis  |
| Ibrutinib              | Imbruvica®          | 140mg, 280mg, 420mg,<br>560mg | Tablets        | Chronic Lymphocytic Leukemia/Small<br>Lymphocytic Lymphoma, Waldenström's<br>Macroglobulinemia, Mantle Cell Lymphoma <sup>1</sup> ,<br>Chronic Graft-Versus-Host Disease <sup>2</sup> |
| Lenvatinib             | Lenvima®/Kisplyx®   | 4mg, 10mg                     | Tablets        | Renal Cell, Hepatocellular and Endometrial<br>Carcinomas, Differentiated Thyroid Cancer   |
| Nilotinib              | Tasigna®            | 50mg, 150mg, 200mg            | Capsules       | Chronic Myeloid Leukemia  |
| Olaparib               | Lynparza®           | 100mg, 150mg                  | Tablets        | Ovarian, Breast, Pancreatic and Prostate<br>Cancer  |
| Palbociclib            | lbrance®            | 75mg, 100mg, 125mg            | Tablets        | Breast Cancer   |
| Palbociclib            | lbrance®            | 75mg, 100mg, 125mg            | Capsules       | Breast Cancer   |
| Pazopanib              | Votrient®           | 200mg, 400mg                  | Tablets        | Renal Cell Carcinoma, Soft Tissue Sarcoma   |
| Pomalidomide           | Imnovid®/Pomalyst®  | 1mg, 2mg, 3mg, 4mg            | Capsules       | Multiple Myeloma, Kaposi Sarcoma <sup>2</sup>   |
| Ruxolitinib            | Jakavi®/Jakafi®     | 5mg, 10mg, 15mg, 20mg         | Tablets        | Myelofibrosis, Polycythemia Vera, Acute and<br>Chronic Graft-Versus-Host Disease  |
| Sunitinib              | Sutent®             | 12.5mg, 25mg, 37.5mg, 50mg    | Capsules       | Gastrointestinal Stromal Tumor, Renal Cell<br>Carcinoma   |
| Tofacitinib            | Xeljanz®            | 5mg, 10mg                     | Tablets        | Rheumatoid and Psoriatic Arthritis,<br>Ulcerative Colitis, Ankylosing Spondylitis,<br>Polyarticular Course Juvenile Idiopathic<br>Arthritis   |
| Tofacitinib XR         | Xeljanz XR®         | 11mg, 22mg                    | Tablets        | Rheumatoid and Psoriatic Arthritis,<br>Ulcerative Colitis, Ankylosing Spondylitis   |
|                        |                     |                               |                |   |

 $<sup>^{1}\</sup>mbox{Approved}$  only by EMA.  $^{2}\mbox{Approved}$  only by FDA.

### **ON**Concept® Services

Pooling the complementary skills and competencies of Bluepharma, Welding and Helm, the ONConcept® covers the entire value chain - from portfolio building to product development and market supply.



#### **Intellectual Property (IP) Support**

- In-depth IP analysis by highly qualified, in-house team.
- Extensive experience in prosecution and challenge of IP.



#### **API Sourcing**

- API procurement based on over 60 years of experience.
- Global network of established partnerships and cooperations.



#### FDF Development, Manufacturing and Supply Chain

- EU-GMP approved unit, furthermore successfully inspected six times by USFDA (2009, 2012, 2014, 2016, 2019) as well as by MFDS (South Korea), MOHME Libya, SFDA (Saudi Arabia) and ANVISA (Brazil).
- · Manufacturing within site inspected by authorities, GMP-approved and located in Portugal.
- Reliable and consistent supply from API and raw materials to commercial manufacturing.



#### **Clinical Development**

- · Development of clinical programs according to international standards by in-house experts.
- Conduct of clinical trials at European-based FDA-inspected CRO for Bioequivalence and Phase I studies.



#### **Regulatory Support**

· Quick and smooth registration procedures according to latest EU/US requirements based on scientific and regulatory expertise.







## Be our commercial partner

**Empower your portfolio** and **consolidate your supply chain** through an attractive business model and exclusive commercial conditions.

#### For business inquiries:

business@onconceptpharma.com

www.onconceptpharma.com

#### Bluepharma Indústria Farmacêutica, SA

Coimbra • Portugal

Phone +351 239 800 300

E-Mail business@bluepharma.pt

www.bluepharmagroup.com

#### Welding GmbH & Co. KG

Hamburg • Germany

Phone +49 40 35908 - 0

E-Mail mailbox@welding.eu

www.welding.eu

#### **Helm AG**

Hamburg • Germany

Phone +49 40 23 75 0

E-Mail info@helmag.com

www.helmag.com



